Loading
CLIO-8421 is an experimental dual-payload antibody-drug conjugate from Callio Therapeutics, in preclinical development for non-small cell lung cancer and metastatic breast cancer.
CLIO-8421 is a dual-payload antibody-drug conjugate from Callio Therapeutics. A TROP2-directed dual-payload ADC; the company names only the target. Its furthest stage is preclinical development, for non-small cell lung cancer and metastatic breast cancer. No clinical trial naming it is registered on ClinicalTrials.gov. IND-enabling on the company pipeline chart. It has not been shown to work in people.
A TROP2-directed dual-payload ADC; the company names only the target. Connects to TROP2.
1.CLIO-8421's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CLIO-8421" OR ABSTRACT:"CLIO-8421") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CLIO-8421, not a curated reading list.
Shares Callio Therapeutics and the tag pipeline.
Shares Callio Therapeutics and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Shares TROP2 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/